APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti Influenza Virus Chinese Medicine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anti Influenza Virus Chinese Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026196 pages

Choose your research edition.

Industry ResearchAnti Influenza Virus Chinese Medicine Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti Influenza Virus Chinese Medicine Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Anti Influenza Virus Chinese Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti Influenza Virus Chinese Medicine Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti Influenza Virus Chinese Medicine Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Anti Influenza Virus Chinese Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anti Influenza Virus Chinese Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti Influenza Virus Chinese Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti Influenza Virus Chinese Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anti Influenza Virus Chinese Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti Influenza Virus Chinese Medicine include China TCM, ZBD Pharmaceutical, Zhejiang Kanglaite Pharmaceutical, Zhejiang Conba Pharmaceutical, Changbaishan Pharmaceutical, Yunnan Baiyao, Yiling Pharmaceutical, Wuzhou Pharmaceutical and Tongrentang, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti Influenza Virus Chinese Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti Influenza Virus Chinese Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti Influenza Virus Chinese Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti Influenza Virus Chinese Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti Influenza Virus Chinese Medicine Segment by Company

China TCM

ZBD Pharmaceutical

Zhejiang Kanglaite Pharmaceutical

Zhejiang Conba Pharmaceutical

Changbaishan Pharmaceutical

Yunnan Baiyao

Yiling Pharmaceutical

Wuzhou Pharmaceutical

Tongrentang

Yusheng Pharmaceutical

TASLY

Chase Sun Pharmaceutical

Green Valley Pharma

Livzon

Qingfeng Pharmaceutical Group

Jumpcan

CR SANJIU

Gerun Pharmaceutical

Fusen Pharmaceutical

Shineway Pharmaceutical

Harbin Pharmaceutical Group

Harbin Pharmaceutical Group

Guangzhou Pharmaceutical

Buchang Pharmaceutical

Anti Influenza Virus Chinese Medicine Segment by Type

Injection

Syrup

Aerosol

Oral Solution

Particles

Chewable Tablets

Capsule

Lozenges

Pills

Anti Influenza Virus Chinese Medicine Segment by Application

Adult

Children

Anti Influenza Virus Chinese Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti Influenza Virus Chinese Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti Influenza Virus Chinese Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti Influenza Virus Chinese Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti Influenza Virus Chinese Medicine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti Influenza Virus Chinese Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anti Influenza Virus Chinese Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anti Influenza Virus Chinese Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anti Influenza Virus Chinese Medicine Industry Trends Table 2. Anti Influenza Virus Chinese Medicine Industry Drivers Table 3. Anti Influenza Virus Chinese Medicine Industry Opportunities and Challenges Table 4. Anti Influenza Virus Chinese Medicine Industry Restraints Table 5. Global Anti Influenza Virus Chinese Medicine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anti Influenza Virus Chinese Medicine Sales by Manufacturers (K Tons) & (2021-2026) Table 8. Global Anti Influenza Virus Chinese Medicine Sales Market Share by Manufacturers Table 9. Global Anti Influenza Virus Chinese Medicine Average Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 10. Global Anti Influenza Virus Chinese Medicine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anti Influenza Virus Chinese Medicine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anti Influenza Virus Chinese Medicine Manufacturers, Product Type & Application Table 13. Global Anti Influenza Virus Chinese Medicine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti Influenza Virus Chinese Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Injection Table 17. Major Manufacturers of Syrup Table 18. Major Manufacturers of Aerosol Table 19. Major Manufacturers of Oral Solution Table 20. Major Manufacturers of Particles Table 21. Major Manufacturers of Chewable Tablets Table 22. Major Manufacturers of Capsule Table 23. Major Manufacturers of Lozenges Table 24. Major Manufacturers of Pills Table 25. Global Anti Influenza Virus Chinese Medicine Sales by Type 2021 VS 2025 VS 2032 (K Tons) Table 26. Global Anti Influenza Virus Chinese Medicine Sales by Type (2021-2026) & (K Tons) Table 27. Global Anti Influenza Virus Chinese Medicine Sales by Type (2027-2032) & (K Tons) Table 28. Global Anti Influenza Virus Chinese Medicine Sales Market Share by Type (2021-2026) Table 29. Global Anti Influenza Virus Chinese Medicine Sales Market Share by Type (2027-2032) Table 30. Global Anti Influenza Virus Chinese Medicine Revenue by Type 2021 VS 2025 VS 2032 (K Tons) Table 31. Global Anti Influenza Virus Chinese Medicine Revenue by Type (2021-2026) & (K Tons) Table 32. Global Anti Influenza Virus Chinese Medicine Revenue by Type (2027-2032) & (K Tons) Table 33. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Type (2021-2026) Table 34. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Type (2027-2032) Table 35. Major Manufacturers of Adult Table 36. Major Manufacturers of Children Table 37. Global Anti Influenza Virus Chinese Medicine Sales by Application 2021 VS 2025 VS 2032 (K Tons) Table 38. Global Anti Influenza Virus Chinese Medicine Sales by Application (2021-2026) & (K Tons) Table 39. Global Anti Influenza Virus Chinese Medicine Sales by Application (2027-2032) & (K Tons) Table 40. Global Anti Influenza Virus Chinese Medicine Sales Market Share by Application (2021-2026) Table 41. Global Anti Influenza Virus Chinese Medicine Sales Market Share by Application (2027-2032) Table 42. Global Anti Influenza Virus Chinese Medicine Revenue by Application 2021 VS 2025 VS 2032 (K Tons) Table 43. Global Anti Influenza Virus Chinese Medicine Revenue by Application (2021-2026) & (K Tons) Table 44. Global Anti Influenza Virus Chinese Medicine Revenue by Application (2027-2032) & (K Tons) Table 45. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Application (2021-2026) Table 46. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Application (2027-2032) Table 47. Global Anti Influenza Virus Chinese Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Table 48. Global Anti Influenza Virus Chinese Medicine Sales by Region (2021-2026) & (K Tons) Table 49. Global Anti Influenza Virus Chinese Medicine Sales Market Share by Region (2021-2026) Table 50. Global Anti Influenza Virus Chinese Medicine Sales Forecasted by Region (2027-2032) & (K Tons) Table 51. Global Anti Influenza Virus Chinese Medicine Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Anti Influenza Virus Chinese Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 53. North America Anti Influenza Virus Chinese Medicine Sales by Country (2021-2026) & (K Tons) Table 54. North America Anti Influenza Virus Chinese Medicine Sales by Country (2027-2032) & (K Tons) Table 55. Europe Anti Influenza Virus Chinese Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 56. Europe Anti Influenza Virus Chinese Medicine Sales by Country (2021-2026) & (K Tons) Table 57. Europe Anti Influenza Virus Chinese Medicine Sales by Country (2027-2032) & (K Tons) Table 58. Asia Pacific Anti Influenza Virus Chinese Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 59. Asia Pacific Anti Influenza Virus Chinese Medicine Sales by Country (2021-2026) & (K Tons) Table 60. Asia Pacific Anti Influenza Virus Chinese Medicine Sales by Country (2027-2032) & (K Tons) Table 61. South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 62. South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Sales by Country (2021-2026) & (K Tons) Table 63. South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Sales by Country (2027-2032) & (K Tons) Table 64. Global Anti Influenza Virus Chinese Medicine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Anti Influenza Virus Chinese Medicine Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Anti Influenza Virus Chinese Medicine Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Region (2021-2026) Table 68. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Region (2027-2032) Table 69. China TCM Company Information Table 70. China TCM Business Overview Table 71. China TCM Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. China TCM Anti Influenza Virus Chinese Medicine Product Portfolio Table 73. China TCM Recent Development Table 74. ZBD Pharmaceutical Company Information Table 75. ZBD Pharmaceutical Business Overview Table 76. ZBD Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. ZBD Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 78. ZBD Pharmaceutical Recent Development Table 79. Zhejiang Kanglaite Pharmaceutical Company Information Table 80. Zhejiang Kanglaite Pharmaceutical Business Overview Table 81. Zhejiang Kanglaite Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Zhejiang Kanglaite Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 83. Zhejiang Kanglaite Pharmaceutical Recent Development Table 84. Zhejiang Conba Pharmaceutical Company Information Table 85. Zhejiang Conba Pharmaceutical Business Overview Table 86. Zhejiang Conba Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Zhejiang Conba Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 88. Zhejiang Conba Pharmaceutical Recent Development Table 89. Changbaishan Pharmaceutical Company Information Table 90. Changbaishan Pharmaceutical Business Overview Table 91. Changbaishan Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Changbaishan Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 93. Changbaishan Pharmaceutical Recent Development Table 94. Yunnan Baiyao Company Information Table 95. Yunnan Baiyao Business Overview Table 96. Yunnan Baiyao Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Yunnan Baiyao Anti Influenza Virus Chinese Medicine Product Portfolio Table 98. Yunnan Baiyao Recent Development Table 99. Yiling Pharmaceutical Company Information Table 100. Yiling Pharmaceutical Business Overview Table 101. Yiling Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Yiling Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 103. Yiling Pharmaceutical Recent Development Table 104. Wuzhou Pharmaceutical Company Information Table 105. Wuzhou Pharmaceutical Business Overview Table 106. Wuzhou Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Wuzhou Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 108. Wuzhou Pharmaceutical Recent Development Table 109. Tongrentang Company Information Table 110. Tongrentang Business Overview Table 111. Tongrentang Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Tongrentang Anti Influenza Virus Chinese Medicine Product Portfolio Table 113. Tongrentang Recent Development Table 114. Yusheng Pharmaceutical Company Information Table 115. Yusheng Pharmaceutical Business Overview Table 116. Yusheng Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Yusheng Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 118. Yusheng Pharmaceutical Recent Development Table 119. TASLY Company Information Table 120. TASLY Business Overview Table 121. TASLY Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. TASLY Anti Influenza Virus Chinese Medicine Product Portfolio Table 123. TASLY Recent Development Table 124. Chase Sun Pharmaceutical Company Information Table 125. Chase Sun Pharmaceutical Business Overview Table 126. Chase Sun Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Chase Sun Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 128. Chase Sun Pharmaceutical Recent Development Table 129. Green Valley Pharma Company Information Table 130. Green Valley Pharma Business Overview Table 131. Green Valley Pharma Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Green Valley Pharma Anti Influenza Virus Chinese Medicine Product Portfolio Table 133. Green Valley Pharma Recent Development Table 134. Livzon Company Information Table 135. Livzon Business Overview Table 136. Livzon Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Livzon Anti Influenza Virus Chinese Medicine Product Portfolio Table 138. Livzon Recent Development Table 139. Qingfeng Pharmaceutical Group Company Information Table 140. Qingfeng Pharmaceutical Group Business Overview Table 141. Qingfeng Pharmaceutical Group Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Qingfeng Pharmaceutical Group Anti Influenza Virus Chinese Medicine Product Portfolio Table 143. Qingfeng Pharmaceutical Group Recent Development Table 144. Jumpcan Company Information Table 145. Jumpcan Business Overview Table 146. Jumpcan Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Jumpcan Anti Influenza Virus Chinese Medicine Product Portfolio Table 148. Jumpcan Recent Development Table 149. CR SANJIU Company Information Table 150. CR SANJIU Business Overview Table 151. CR SANJIU Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. CR SANJIU Anti Influenza Virus Chinese Medicine Product Portfolio Table 153. CR SANJIU Recent Development Table 154. Gerun Pharmaceutical Company Information Table 155. Gerun Pharmaceutical Business Overview Table 156. Gerun Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 157. Gerun Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 158. Gerun Pharmaceutical Recent Development Table 159. Fusen Pharmaceutical Company Information Table 160. Fusen Pharmaceutical Business Overview Table 161. Fusen Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 162. Fusen Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 163. Fusen Pharmaceutical Recent Development Table 164. Shineway Pharmaceutical Company Information Table 165. Shineway Pharmaceutical Business Overview Table 166. Shineway Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 167. Shineway Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 168. Shineway Pharmaceutical Recent Development Table 169. Harbin Pharmaceutical Group Company Information Table 170. Harbin Pharmaceutical Group Business Overview Table 171. Harbin Pharmaceutical Group Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 172. Harbin Pharmaceutical Group Anti Influenza Virus Chinese Medicine Product Portfolio Table 173. Harbin Pharmaceutical Group Recent Development Table 174. Harbin Pharmaceutical Group Company Information Table 175. Harbin Pharmaceutical Group Business Overview Table 176. Harbin Pharmaceutical Group Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 177. Harbin Pharmaceutical Group Anti Influenza Virus Chinese Medicine Product Portfolio Table 178. Harbin Pharmaceutical Group Recent Development Table 179. Guangzhou Pharmaceutical Company Information Table 180. Guangzhou Pharmaceutical Business Overview Table 181. Guangzhou Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 182. Guangzhou Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 183. Guangzhou Pharmaceutical Recent Development Table 184. Buchang Pharmaceutical Company Information Table 185. Buchang Pharmaceutical Business Overview Table 186. Buchang Pharmaceutical Anti Influenza Virus Chinese Medicine Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 187. Buchang Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio Table 188. Buchang Pharmaceutical Recent Development Table 189. Key Raw Materials Table 190. Raw Materials Key Suppliers Table 191. Anti Influenza Virus Chinese Medicine Distributors List Table 192. Anti Influenza Virus Chinese Medicine Customers List Table 193. Research Programs/Design for This Report Table 194. Authors List of This Report Table 195. Secondary Sources Table 196. Primary Sources List of Figures Figure 1. Anti Influenza Virus Chinese Medicine Product Image Figure 2. Global Anti Influenza Virus Chinese Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti Influenza Virus Chinese Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti Influenza Virus Chinese Medicine Sales (2021-2032) & (K Tons) Figure 5. Global Anti Influenza Virus Chinese Medicine Average Price (US$/Ton) & (2021-2032) Figure 6. Global Top 5 and 10 Anti Influenza Virus Chinese Medicine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Injection Image Figure 9. Syrup Image Figure 10. Aerosol Image Figure 11. Oral Solution Image Figure 12. Particles Image Figure 13. Chewable Tablets Image Figure 14. Capsule Image Figure 15. Lozenges Image Figure 16. Pills Image Figure 17. Global Anti Influenza Virus Chinese Medicine Sales by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 18. Global Anti Influenza Virus Chinese Medicine Sales Market Share 2021 VS 2025 VS 2032 Figure 19. Global Anti Influenza Virus Chinese Medicine Sales Market Share by Type (2021-2032) Figure 20. Global Anti Influenza Virus Chinese Medicine Revenue by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 21. Global Anti Influenza Virus Chinese Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Type (2021-2032) Figure 23. Adult Image Figure 24. Children Image Figure 25. Global Anti Influenza Virus Chinese Medicine Sales by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 26. Global Anti Influenza Virus Chinese Medicine Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Anti Influenza Virus Chinese Medicine Sales Market Share by Application (2021-2032) Figure 28. Global Anti Influenza Virus Chinese Medicine Revenue by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 29. Global Anti Influenza Virus Chinese Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Application (2021-2032) Figure 31. North America Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 32. North America Anti Influenza Virus Chinese Medicine Sales Market Share by Country (2021-2032) Figure 33. U.S. Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 34. Canada Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 35. Mexico Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 36. Europe Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 37. Europe Anti Influenza Virus Chinese Medicine Sales Market Share by Country (2021-2032) Figure 38. Germany Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 39. France Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 40. U.K. Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 41. Italy Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 42. Netherlands Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 43. Asia Pacific Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 44. Asia Pacific Anti Influenza Virus Chinese Medicine Sales Market Share by Country (2021-2032) Figure 45. China Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 46. Japan Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 47. South Korea Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 48. Southeast Asia Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 49. India Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 50. Australia Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 51. South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 52. South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Sales Market Share by Country (2021-2032) Figure 53. Brazil Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 54. South Africa Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 55. Saudi Arabia Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 56. Turkey Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 57. Argentina Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 58. UAE Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 59. Egypt Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 60. Chile Anti Influenza Virus Chinese Medicine Sales and Growth Rate (2021-2032) & (K Tons) Figure 61. Global Anti Influenza Virus Chinese Medicine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Anti Influenza Virus Chinese Medicine Revenue (2021-2032) & (US$ Million) Figure 64. North America Anti Influenza Virus Chinese Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Anti Influenza Virus Chinese Medicine Revenue (2021-2032) & (US$ Million) Figure 66. Europe Anti Influenza Virus Chinese Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Anti Influenza Virus Chinese Medicine Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Anti Influenza Virus Chinese Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Anti Influenza Virus Chinese Medicine Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Anti Influenza Virus Chinese Medicine Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Syrup
  • Aerosol
  • Oral Solution
  • Particles
  • Chewable Tablets
  • Capsule
  • Lozenges
  • Pills
Applications
  • Adult
  • Children
Companies covered
  • China TCM
  • ZBD Pharmaceutical
  • Zhejiang Kanglaite Pharmaceutical
  • Zhejiang Conba Pharmaceutical
  • Changbaishan Pharmaceutical
  • Yunnan Baiyao
  • Yiling Pharmaceutical
  • Wuzhou Pharmaceutical
  • Tongrentang
  • Yusheng Pharmaceutical
  • TASLY
  • Chase Sun Pharmaceutical
  • Green Valley Pharma
  • Livzon
  • Qingfeng Pharmaceutical Group
  • Jumpcan
  • CR SANJIU
  • Gerun Pharmaceutical
  • Fusen Pharmaceutical
  • Shineway Pharmaceutical
  • Harbin Pharmaceutical Group
  • Harbin Pharmaceutical Group
  • Guangzhou Pharmaceutical
  • Buchang Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti Influenza Virus Chinese Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti Influenza Virus Chinese Medicine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anti Influenza Virus Chinese Medicine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anti Influenza Virus Chinese Medicine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anti Influenza Virus Chinese Medicine Market Dynamics
  1. 2.1 Anti Influenza Virus Chinese Medicine Industry Trends
  2. 2.2 Anti Influenza Virus Chinese Medicine Industry Drivers
  3. 2.3 Anti Influenza Virus Chinese Medicine Industry Opportunities and Challenges
  4. 2.4 Anti Influenza Virus Chinese Medicine Industry Restraints
3 Anti Influenza Virus Chinese Medicine Market by Manufacturers
  1. 3.1 Global Anti Influenza Virus Chinese Medicine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anti Influenza Virus Chinese Medicine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anti Influenza Virus Chinese Medicine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anti Influenza Virus Chinese Medicine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti Influenza Virus Chinese Medicine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anti Influenza Virus Chinese Medicine Manufacturers, Product Type & Application
  7. 3.7 Global Anti Influenza Virus Chinese Medicine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti Influenza Virus Chinese Medicine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti Influenza Virus Chinese Medicine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti Influenza Virus Chinese Medicine Tier 1, Tier 2, and Tier 3
4 Anti Influenza Virus Chinese Medicine Market by Type
  1. 4.1 Anti Influenza Virus Chinese Medicine Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Syrup
  4. 4.1.3 Aerosol
  5. 4.1.4 Oral Solution
  6. 4.1.5 Particles
  7. 4.1.6 Chewable Tablets
  8. 4.1.7 Capsule
  9. 4.1.8 Lozenges
  10. 4.1.9 Pills
  11. 4.2 Global Anti Influenza Virus Chinese Medicine Sales by Type
  12. 4.2.1 Global Anti Influenza Virus Chinese Medicine Sales by Type (2021 VS 2025 VS 2032)
  13. 4.2.2 Global Anti Influenza Virus Chinese Medicine Sales by Type (2021-2032)
  14. 4.2.3 Global Anti Influenza Virus Chinese Medicine Sales Market Share by Type (2021-2032)
  15. 4.3 Global Anti Influenza Virus Chinese Medicine Revenue by Type
  16. 4.3.1 Global Anti Influenza Virus Chinese Medicine Revenue by Type (2021 VS 2025 VS 2032)
  17. 4.3.2 Global Anti Influenza Virus Chinese Medicine Revenue by Type (2021-2032)
  18. 4.3.3 Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Type (2021-2032)
5 Anti Influenza Virus Chinese Medicine Market by Application
  1. 5.1 Anti Influenza Virus Chinese Medicine Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Children
  4. 5.2 Global Anti Influenza Virus Chinese Medicine Sales by Application
  5. 5.2.1 Global Anti Influenza Virus Chinese Medicine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Anti Influenza Virus Chinese Medicine Sales by Application (2021-2032)
  7. 5.2.3 Global Anti Influenza Virus Chinese Medicine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Anti Influenza Virus Chinese Medicine Revenue by Application
  9. 5.3.1 Global Anti Influenza Virus Chinese Medicine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Anti Influenza Virus Chinese Medicine Revenue by Application (2021-2032)
  11. 5.3.3 Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Application (2021-2032)
6 Global Anti Influenza Virus Chinese Medicine Sales by Region
  1. 6.1 Global Anti Influenza Virus Chinese Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti Influenza Virus Chinese Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Anti Influenza Virus Chinese Medicine Sales by Region (2021-2026)
  4. 6.2.2 Global Anti Influenza Virus Chinese Medicine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti Influenza Virus Chinese Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anti Influenza Virus Chinese Medicine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anti Influenza Virus Chinese Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anti Influenza Virus Chinese Medicine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anti Influenza Virus Chinese Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anti Influenza Virus Chinese Medicine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anti Influenza Virus Chinese Medicine Revenue by Region
  1. 7.1 Global Anti Influenza Virus Chinese Medicine Revenue by Region
  2. 7.1.1 Global Anti Influenza Virus Chinese Medicine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anti Influenza Virus Chinese Medicine Revenue by Region (2021-2026)
  4. 7.1.3 Global Anti Influenza Virus Chinese Medicine Revenue by Region (2027-2032)
  5. 7.1.4 Global Anti Influenza Virus Chinese Medicine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anti Influenza Virus Chinese Medicine Revenue (2021-2032)
  8. 7.2.2 North America Anti Influenza Virus Chinese Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anti Influenza Virus Chinese Medicine Revenue (2021-2032)
  11. 7.3.2 Europe Anti Influenza Virus Chinese Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anti Influenza Virus Chinese Medicine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anti Influenza Virus Chinese Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anti Influenza Virus Chinese Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 China TCM
  2. 8.1.1 China TCM Company Information
  3. 8.1.2 China TCM Business Overview
  4. 8.1.3 China TCM Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 China TCM Anti Influenza Virus Chinese Medicine Product Portfolio
  6. 8.1.5 China TCM Recent Developments
  7. 8.2 ZBD Pharmaceutical
  8. 8.2.1 ZBD Pharmaceutical Company Information
  9. 8.2.2 ZBD Pharmaceutical Business Overview
  10. 8.2.3 ZBD Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ZBD Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  12. 8.2.5 ZBD Pharmaceutical Recent Developments
  13. 8.3 Zhejiang Kanglaite Pharmaceutical
  14. 8.3.1 Zhejiang Kanglaite Pharmaceutical Company Information
  15. 8.3.2 Zhejiang Kanglaite Pharmaceutical Business Overview
  16. 8.3.3 Zhejiang Kanglaite Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zhejiang Kanglaite Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  18. 8.3.5 Zhejiang Kanglaite Pharmaceutical Recent Developments
  19. 8.4 Zhejiang Conba Pharmaceutical
  20. 8.4.1 Zhejiang Conba Pharmaceutical Company Information
  21. 8.4.2 Zhejiang Conba Pharmaceutical Business Overview
  22. 8.4.3 Zhejiang Conba Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zhejiang Conba Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  24. 8.4.5 Zhejiang Conba Pharmaceutical Recent Developments
  25. 8.5 Changbaishan Pharmaceutical
  26. 8.5.1 Changbaishan Pharmaceutical Company Information
  27. 8.5.2 Changbaishan Pharmaceutical Business Overview
  28. 8.5.3 Changbaishan Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Changbaishan Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  30. 8.5.5 Changbaishan Pharmaceutical Recent Developments
  31. 8.6 Yunnan Baiyao
  32. 8.6.1 Yunnan Baiyao Company Information
  33. 8.6.2 Yunnan Baiyao Business Overview
  34. 8.6.3 Yunnan Baiyao Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Yunnan Baiyao Anti Influenza Virus Chinese Medicine Product Portfolio
  36. 8.6.5 Yunnan Baiyao Recent Developments
  37. 8.7 Yiling Pharmaceutical
  38. 8.7.1 Yiling Pharmaceutical Company Information
  39. 8.7.2 Yiling Pharmaceutical Business Overview
  40. 8.7.3 Yiling Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Yiling Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  42. 8.7.5 Yiling Pharmaceutical Recent Developments
  43. 8.8 Wuzhou Pharmaceutical
  44. 8.8.1 Wuzhou Pharmaceutical Company Information
  45. 8.8.2 Wuzhou Pharmaceutical Business Overview
  46. 8.8.3 Wuzhou Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Wuzhou Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  48. 8.8.5 Wuzhou Pharmaceutical Recent Developments
  49. 8.9 Tongrentang
  50. 8.9.1 Tongrentang Company Information
  51. 8.9.2 Tongrentang Business Overview
  52. 8.9.3 Tongrentang Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Tongrentang Anti Influenza Virus Chinese Medicine Product Portfolio
  54. 8.9.5 Tongrentang Recent Developments
  55. 8.10 Yusheng Pharmaceutical
  56. 8.10.1 Yusheng Pharmaceutical Company Information
  57. 8.10.2 Yusheng Pharmaceutical Business Overview
  58. 8.10.3 Yusheng Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Yusheng Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  60. 8.10.5 Yusheng Pharmaceutical Recent Developments
  61. 8.11 TASLY
  62. 8.11.1 TASLY Company Information
  63. 8.11.2 TASLY Business Overview
  64. 8.11.3 TASLY Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 TASLY Anti Influenza Virus Chinese Medicine Product Portfolio
  66. 8.11.5 TASLY Recent Developments
  67. 8.12 Chase Sun Pharmaceutical
  68. 8.12.1 Chase Sun Pharmaceutical Company Information
  69. 8.12.2 Chase Sun Pharmaceutical Business Overview
  70. 8.12.3 Chase Sun Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Chase Sun Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  72. 8.12.5 Chase Sun Pharmaceutical Recent Developments
  73. 8.13 Green Valley Pharma
  74. 8.13.1 Green Valley Pharma Company Information
  75. 8.13.2 Green Valley Pharma Business Overview
  76. 8.13.3 Green Valley Pharma Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Green Valley Pharma Anti Influenza Virus Chinese Medicine Product Portfolio
  78. 8.13.5 Green Valley Pharma Recent Developments
  79. 8.14 Livzon
  80. 8.14.1 Livzon Company Information
  81. 8.14.2 Livzon Business Overview
  82. 8.14.3 Livzon Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Livzon Anti Influenza Virus Chinese Medicine Product Portfolio
  84. 8.14.5 Livzon Recent Developments
  85. 8.15 Qingfeng Pharmaceutical Group
  86. 8.15.1 Qingfeng Pharmaceutical Group Company Information
  87. 8.15.2 Qingfeng Pharmaceutical Group Business Overview
  88. 8.15.3 Qingfeng Pharmaceutical Group Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Qingfeng Pharmaceutical Group Anti Influenza Virus Chinese Medicine Product Portfolio
  90. 8.15.5 Qingfeng Pharmaceutical Group Recent Developments
  91. 8.16 Jumpcan
  92. 8.16.1 Jumpcan Company Information
  93. 8.16.2 Jumpcan Business Overview
  94. 8.16.3 Jumpcan Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Jumpcan Anti Influenza Virus Chinese Medicine Product Portfolio
  96. 8.16.5 Jumpcan Recent Developments
  97. 8.17 CR SANJIU
  98. 8.17.1 CR SANJIU Company Information
  99. 8.17.2 CR SANJIU Business Overview
  100. 8.17.3 CR SANJIU Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CR SANJIU Anti Influenza Virus Chinese Medicine Product Portfolio
  102. 8.17.5 CR SANJIU Recent Developments
  103. 8.18 Gerun Pharmaceutical
  104. 8.18.1 Gerun Pharmaceutical Company Information
  105. 8.18.2 Gerun Pharmaceutical Business Overview
  106. 8.18.3 Gerun Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Gerun Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  108. 8.18.5 Gerun Pharmaceutical Recent Developments
  109. 8.19 Fusen Pharmaceutical
  110. 8.19.1 Fusen Pharmaceutical Company Information
  111. 8.19.2 Fusen Pharmaceutical Business Overview
  112. 8.19.3 Fusen Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Fusen Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  114. 8.19.5 Fusen Pharmaceutical Recent Developments
  115. 8.20 Shineway Pharmaceutical
  116. 8.20.1 Shineway Pharmaceutical Company Information
  117. 8.20.2 Shineway Pharmaceutical Business Overview
  118. 8.20.3 Shineway Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Shineway Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  120. 8.20.5 Shineway Pharmaceutical Recent Developments
  121. 8.21 Harbin Pharmaceutical Group
  122. 8.21.1 Harbin Pharmaceutical Group Company Information
  123. 8.21.2 Harbin Pharmaceutical Group Business Overview
  124. 8.21.3 Harbin Pharmaceutical Group Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Harbin Pharmaceutical Group Anti Influenza Virus Chinese Medicine Product Portfolio
  126. 8.21.5 Harbin Pharmaceutical Group Recent Developments
  127. 8.22 Harbin Pharmaceutical Group
  128. 8.22.1 Harbin Pharmaceutical Group Company Information
  129. 8.22.2 Harbin Pharmaceutical Group Business Overview
  130. 8.22.3 Harbin Pharmaceutical Group Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Harbin Pharmaceutical Group Anti Influenza Virus Chinese Medicine Product Portfolio
  132. 8.22.5 Harbin Pharmaceutical Group Recent Developments
  133. 8.23 Guangzhou Pharmaceutical
  134. 8.23.1 Guangzhou Pharmaceutical Company Information
  135. 8.23.2 Guangzhou Pharmaceutical Business Overview
  136. 8.23.3 Guangzhou Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Guangzhou Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  138. 8.23.5 Guangzhou Pharmaceutical Recent Developments
  139. 8.24 Buchang Pharmaceutical
  140. 8.24.1 Buchang Pharmaceutical Company Information
  141. 8.24.2 Buchang Pharmaceutical Business Overview
  142. 8.24.3 Buchang Pharmaceutical Anti Influenza Virus Chinese Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Buchang Pharmaceutical Anti Influenza Virus Chinese Medicine Product Portfolio
  144. 8.24.5 Buchang Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti Influenza Virus Chinese Medicine Value Chain Analysis
  2. 9.1.1 Anti Influenza Virus Chinese Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti Influenza Virus Chinese Medicine Production Mode & Process
  6. 9.2 Anti Influenza Virus Chinese Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti Influenza Virus Chinese Medicine Distributors
  9. 9.2.3 Anti Influenza Virus Chinese Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst